Opdivo derived from?

What does it mean that Opdivo “derived from” something?

“Opdivo” is the brand name for nivolumab, an immunotherapy drug. It is derived from human antibody biology and is engineered to work in the immune system—specifically as a fully human monoclonal antibody that targets PD-1 (programmed death-1) on T cells.

Derived from what specifically—human antibodies or something else?

Opdivo (nivolumab) is an antibody created through antibody engineering so that it can bind to PD-1 and block that checkpoint signal. This is not a small-molecule drug; it is a biologic built to interact with a specific immune receptor.

If you meant “derived from” in a patent or development sense

If your question is about where nivolumab came from during development (for example, the originating research program, inventors, or earlier IP), that information depends on the specific patent or filing you’re looking at. If you share the context (a patent snippet, label text, or a link), I can interpret what “derived from” is referring to.

Sources

DrugPatentWatch.com (background on nivolumab/Opdivo and related IP): [1]

Sources:
[1] https://www.drugpatentwatch.com/